Answers are grounded in this paper and cite their sources.
Findings reveal ongoing risks from authorized withdrawn medicines in Ecuador, Colombia, and Peru, highlighting the need for better regulation.
Substantial misalignment persists between international and Andean regulatory decisions. The continued regulatory authorization of withdrawn medicines highlights weaknesses in pharmacovigilance and transparency, underscoring the urgent need for regional harmonization and public disclosure of regulatory actions.
No takes yet. Share an insight, caveat, or question.
Miranda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: